Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,700,728
  • Shares Outstanding, K 47,190
  • Annual Sales, $ 41,000 K
  • Annual Income, $ -68,360 K
  • 36-Month Beta 3.67
  • Price/Sales 42.82
  • Price/Cash Flow N/A
  • Price/Book 6.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.74
  • Number of Estimates 5
  • High Estimate -0.59
  • Low Estimate -0.83
  • Prior Year -0.62
  • Growth Rate Est. (year over year) -19.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.32 +3.35%
on 10/22/18
47.38 -25.14%
on 09/25/18
-9.02 (-20.27%)
since 09/21/18
3-Month
34.32 +3.35%
on 10/22/18
59.00 -39.88%
on 09/04/18
-22.88 (-39.21%)
since 07/20/18
52-Week
16.51 +114.84%
on 11/09/17
73.90 -52.00%
on 05/24/18
+16.40 (+86.00%)
since 10/20/17

Most Recent Stories

More News
Is a Beat in Store for Vertex (VRTX) This Earnings Season?

On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

CRSP : 35.47 (-1.58%)
CRIS : 1.92 (-6.80%)
VRTX : 177.40 (+0.97%)
AMGN : 198.02 (-1.87%)
Company News For Oct 12, 2018

Companies in the news are: DAL, WBA, COST and CRSP

COST : 229.06 (-0.27%)
CRSP : 35.47 (-1.58%)
WBA : 77.65 (+0.39%)
DAL : 54.24 (+1.59%)
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.

CRSP : 35.47 (-1.58%)
AZN : 39.49 (+0.71%)
SNY : 44.54 (-0.07%)
MACK : 4.26 (+6.23%)
CVS and Bank of America fall while Delta Air Lines climbs

NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:

CRSP : 35.47 (-1.58%)
KMI : 17.44 (-3.00%)
FLR : 46.22 (-0.94%)
SQ : 75.72 (+2.23%)
DAL : 54.24 (+1.59%)
Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Myriad Genetics

NEW YORK, NY / ACCESSWIRE / October 11, 2018 / U.S. equities continued to tumble on Wednesday on rising yields and interest rates. Additionally, weakening tech stocks pressured the S&P 500 to its worst...

CRSP : 35.47 (-1.58%)
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today...

CRSP : 35.47 (-1.58%)
VRTX : 177.40 (+0.97%)
FDA Sets Action Date for Recro's Pain Management Candidate

The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.

CRSP : 35.47 (-1.58%)
AMGN : 198.02 (-1.87%)
ALKS : 38.86 (-3.24%)
REPH : 7.22 (-0.14%)
Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis

Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.

CRSP : 35.47 (-1.58%)
MRUS : 15.29 (-5.62%)
BHC : 24.45 (+0.78%)
AMGN : 198.02 (-1.87%)
Global Stem Cell Market Expected to Reach $270.5 Billion

HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from...

CRSP : 35.47 (-1.58%)
ARNA : 39.13 (-2.16%)
ATHX : 2.02 (-0.49%)
CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive...

CRSP : 35.47 (-1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 39.36
1st Resistance Point 37.70
Last Price 35.47
1st Support Level 35.03
2nd Support Level 34.02

See More

52-Week High 73.90
Fibonacci 61.8% 51.98
Fibonacci 50% 45.21
Fibonacci 38.2% 38.43
Last Price 35.47
52-Week Low 16.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar